Italia markets closed

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
281,73-2,98 (-1,05%)
Alla chiusura: 06:30PM BST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Settore/i
Settore
Impiegati a tempo pieno3.900

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Jeffrey Marc Leiden M.D., Ph.D.Exec. Chairman281,98kN/D1956
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director4,27MN/D1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1,85MN/D1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2,56M197,69k1966
Dr. Ourania Tatsis Ph.D.Exec. VP and Chief Regulatory & Quality Officer1,33MN/D1971
Ms. Kristen C. AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesN/DN/D1977
Dr. David M. Altshuler M.D., Ph.D.Exec. VP of Global Research & Chief Scientific OfficerN/DN/D1965
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/DN/DN/D
Mr. Michael PartridgeSr. VP of Investor RelationsN/DN/DN/D
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerN/DN/D1976
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 1 settembre 2022 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.